Trial site
Evangelisches Krankenhaus Hamm gGmbH
Hamm, 59063, GermanyNot linked to an institution yet
- 8running trials
- 2closed trials
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 41 trial
- Status
- Active, not recruiting6 trials
- Completed2 trials
- Recruiting2 trials
- Lead sponsor
- Bristol-Myers Squibb2 trials
- University Of Cologne2 trials
- German CLL Study Group1 trial
- Goethe University1 trial
- Ipsen1 trial
- and 3 more
Running trials
Recruiting
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· Phase 3· University Of Cologne· Source
Active, not recruiting
AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and
safety of afatinib followed by osimertinib compared to osimertinib in patients with
EGFRmutated/T790M Mutation negative non-squamous NSCLC in the first-line setting
NCT04413201· Phase 4· Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR· Source
Active, not recruiting
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318· Phase 3· German CLL Study Group· Source
Active, not recruiting
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879· Phase 3· Bristol-Myers Squibb· Source
Active, not recruiting
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
NCT03897127· Phase 3· University of Ulm· Source
Active, not recruiting
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
NCT03647878· Ipsen· Source
Recruiting
GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
NCT02872987· Goethe University· Source
Contact: Nicola Gökbuget, Dr. med.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error